key: cord-0856828-gs56qiwx
authors: Lau, C S; Hoo, S P; Yew, S F; Ong, S K; Lum, L T; Heng, P Y; Tan, J G; Wong, M S; Aw, T C
title: Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay
date: 2020-07-27
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfaa134
sha: 332c4b630bbc8d7895a7ffc2d27bb9bf8f9001a9
doc_id: 856828
cord_uid: gs56qiwx

BACKGROUND: Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers. METHODS: We assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 715 coronavirus disease 2019 (COVID-19)-naive samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics. RESULTS: The assay cut-off index (COI) was linear up to 90.8. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. Only 1 case positive for HBsAg tested falsely positive; specificity was 99.9%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at ≥ 21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI ≥1.0) the interval between the last negative and first positive COI (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau. CONCLUSION: The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.

We provide an extensive evaluation of the SARS-CoV-2 antibody assay on the Cobas e801/e602 immunoassay analyser for COVID-19 testing. The assay has good precision, throughput and linear range, with an excellent specificity, sensitivity, positive and negative predictive values when used ≥14 days post-positive PCR. In 11 subjects in whom serum was available prior to a positive antibody signal, the interval between the last negative and first positive reading (time to "sero-conversion") on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the titres to plateau. This lends evidence to the early development of SARS-CoV-2 antibodies. 

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Coronavirus disease 2019 can present with a range of symptoms (1, 2) and inflicts a disturbingly higher fatality rate in older patients (0.32% in those aged <60 years vs 6.4% in those aged ≥60 years) (3). Viral testing (nucleic acid) remains the recommended diagnostic test for infection (4, 5) . However, its long turn-around time has led to calls for more rapid tests like serology. Antibody testing can act as an indirect marker for infection, help identify patients with prior infection or exposure and can be performed relatively

quickly. An immune response can develop (6) as soon as 10-13 days after a COVID-19 infection (7, 8) , However, the early rapid point-of-care tests (POCT) for anti-SARS-CoV-2 were fraught with inaccuracy. Roche Diagnostics has developed a SARS-CoV-2 antibody (anti-SARS-CoV-2) assay for use on its electrochemiluminescent-immunoassay analysers for the rapid, continuous testing of large numbers of samples. This assay has been granted emergency use authorization by the US Food and Drug Administration (FDA) (9) for laboratory use in May 2020. Some brief evaluations of this assay have been recently available as editorial letters (10, 11) . We describe a more extensive evaluation of the Roche anti-SARS-CoV-2 assay on Cobas immunoassay analysers across 3 institutions in Singapore.

We evaluated the Roche anti-SARS-CoV-2 assay in a multi-centre, cross-sectional study that complies with STARD guidelines (see Supplementary table 1 As the Roche anti-SARS-CoV-2 assay is a qualitative test, its sensitivity can be represented by the positive percentage agreement (PPA) between antibody positivity against all PCR positive patients tested. Conversely, the specificity of the test is represented by the negative percentage agreement (NPA) between antibody negativity against all control subjects. No cases with indeterminate or missing results were used in our study.

To study sero-conversion, we examined SARS-CoV-2 PCR positive subjects with residual sera who were initially non-reactive for anti-SARS-CoV-2 but became reactive later.

Statistical analyses were performed using MedCalc software v19.3.1 (MedCalc, Ostend, Belgium). As this work was part of routine evaluation of new diagnostic assays, it was deemed exempt by our institutional review board. 

The Roche assay showed good precision, with a CV of 2.9% for negative controls (mean COI = 0.1) and 5.1% for positive controls (mean COI = 3.0) (See Table 1 ); at higher COI values Supplementary Table 4 ).

Out of the 315 HCWs who received their annual influenza vaccination 4 weeks prior to testing, none were reactive for anti-SARS-CoV-2. In cases positive for other antibodies (n=118), 117

were negative for anti-SARS-CoV-2, however, 1 case that was positive for HBsAg tested positive (false positive) for anti-SARS-CoV-2 (see Table 2 ) with a COI of 1.3.

As there was minimal cross-reactivity with anti-SARS-CoV-2 in the 433 samples above (Table   2 ), we included them in diagnostic specificity analysis together with the other 282 samples from other HCWs. From these 715 samples, the Roche anti-SARS-CoV-2 assay had a specificity of 99.86% (95% CI 99.22 to 100.00).

Of the 349 samples used for sensitivity analysis (from 205 individual patients), the PPA increased to 97.1% (95% CI 90.06 to 99.65) after 14 days post positive PCR (POS), and to 100% after 21 days POS (95% CI 90.26 to 100.00) (see Table 3 ). Notably, 48.2% of patients had positive antibodies within the first week after their PCR diagnosis. Interestingly, of the 66 samples excluded from the sensitivity analyses with late PCR diagnosis (see above), 48.5%

were positive for anti-SARS-CoV-2.

Assuming a disease prevalence of 5%, the predictive value of the Roche anti-SARS-CoV-2 assay (specificity of 99.86% and sensitivity of >97% when used after 14 days POS) will be as follows: positive predictive value (PPV) 97.34% (95% CI 83.75 to 99.62) and negative predictive value (NPV) 99.85% (95%CI 99.41 to 99.96).

Eleven subjects were available for sero-conversion study and the progression of their antibody levels (COI) were plotted against days POS (See Figure 2 and Table 4 They are also in agreement with other evaluations of the Roche anti-SARS-CoV-2 assay in the literature (10, 11, 13) ; the reported assay CV (2.1-4.6%, 1.2-3.6%, <3.9%), test sensitivity at ≥14 days post-onset of symptoms (87.7%, 91.1%, 89.4%) and test specificity (100%, 100%, 98.7%) were similar to ours. This assay easily meets the US Centers for Disease Control and Prevention (CDC) and the FDA requirements for an acceptable SARS-CoV-2 serology test ->90% sensitivity and >95% specificity (14, 15) . As the sensitivity/PPA only increases to over 90% after 14 days post PCR positivity, patients should not be tested earlier. This is also supported by other studies showing that it takes up to 11-14 days before anti-SARS-CoV-2 develop (16) . However, serology may have a role when PCR tests are negative in the face of other clinical symptom suggestive of COVID19. This approach has been proposed in a Chinese study (17) ; using an ELISA IgM they were able to diagnose a family cluster of COVID19 where PCR was negative. The Roche assay has an excellent throughput, analysing 300 samples in 76 minutes. This is a major boon when processing large sample numbers from screening centres.

In our study we have used days POS to categorize our population. As COVID-19 can have asymptomatic and pre-symptomatic patients (18) (19) (20) , using the presence of symptoms as a pre-selection criterion for inclusion will exclude asymptomatic and pre-symptomatic cases; days POS will mitigate against this. Notably, out of 66 leftover serum samples that were available before COVID-19 was suspected and PCR tested positive, 32 were already positive for anti-SARS-CoV-2. From the 11 patients with multiple longitudinal samples in figure 2 , "sero-conversion" (interval between last negative point and first positive point) takes an average of 3 days, and that antibody titres plateau an average of 4 days later. A recent report (8) found that the time course of COVID19 antibodies (both IgG and IgM) tended to plateau in 6 days after they become positive in 19 subjects. Using a Diazyme assay, the median time for IgM seropositivity was 5 days and 4 days for IgG seroconversion (21) . Anti-SARS-CoV-2 has also been detected on the first day of PCR positivity (22) or within 7 days of symptom onset in 12.2% of patients (8) . This indicates that in some patients, anti-SARS-CoV-2 development can occur earlier than expected.

A recent report (23) found that SARS-CoV-2 infection may cause false-positive dengue antibody results; the clinical presentation of these two conditions may be indistinguishable. It is noteworthy that in patients with positive dengue serology (n = 74) we did not encounter any false positive anti-SARS-CoV-2. Our study also confirms that the assay remains specific even in patients positive for HCV, syphilis, ANA, ds-DNA and RF. Moreover, in 315 samples with post-influenza vaccination, none were positive for anti-SARS-CoV-2, reinforcing the fact that the Roche assay has little cross-reactivity with other antibodies. We have since encountered one case of HBV with a false positive anti-SARS-CoV-2. It is likely that as we test more samples, cases of false positive serology will emerge. The sero-negativity of most of our HCWs also underscores the adequacy of our personal protective equipment (PPE) measures.

The PPE measures taken by hospital staff across institutions in Singapore are similar (24) , and include the use of surgical masks in low-risk areas (non-COVID-19 inpatient rooms, afebrile patient zones in the emergency department, non-infectious disease clinics) and N95 respirators/eye protection/gowns/gloves in high-risk areas (COVID-19 isolation rooms, febrile patient zones in the emergency department). However, their lack of antibodies also means that most of these HCWs remain at risk for future COVID-19 infections and they should continue to rigorously enforce safety precautions.

The strength of this evaluation is that it is a multi-center collaborative effort with sufficient sample numbers for sensitivity, specificity, and cross-reactivity analyses. A limitation of our study is that we have relatively fewer samples for cases after 14 days POS. Further studies on larger populations would be desirable. In addition, we do not have the sero-prevalence of SARS-CoV-2 in our community. However, it is to be expected that in areas with low prevalence of COVID-19 (<1%), high false positive rates will be encountered. At the time of this study, we created our own negative and positive control materials from patient sera based on manufacturer recommendations. However, control materials have since been supplied by the manufacturer. The on-board reagent stability of 72 hours in the initial manufacturer information sheet has now been updated to 14 days.

Our results show that the Roche anti-SARS-CoV-2 assay has excellent performance and is highly comparable both with the manufacturer's information and other published studies. With an excellent throughput, the Cobas e801 should be extremely useful in the tracking the spread * based on interpolation from figure 2.

Abbreviations: POS: Post-positive PCR, COI: Cut-off index. 

Mild or Moderate Covid-19

Severe Covid-19

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease

The Royal College of Pathologists of Australia. Position Statement, COVID19 IgG/IgM Rapid POCT Tests

Food and Drug Administration. Important Information on the Use of Serological (Antibody) Tests for COVID-19 -Letter to Health Care Providers

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for 2 detecting antibodies against SARS-CoV2

Antibody Responses to SARS-CoV-2 in Patients With COVID-19

United States Food and Drug Administration

Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies

Clinical Performance of the Roche SARS-CoV-2 Serologic Assay

User Verification of Precision and Estimation of Bias; Approved Guideline-Third Edition, CLSI document EP15-A3

Evaluation of the Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARSCoV-2 antibodies

EUA Authorized Serology Test Performance

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease

Profiling early humoral response to diagnose novel corona disease (COVID-19)

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Presymptomatic Transmission of SARS-CoV-2 -Singapore

Asymptomatic and Presymptomatic Infectors: Hidden Sources of COVID-19 Disease

Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Covert COVID-19 and falsepositive dengue serology in Singapore

Responding to the COVID-19 Outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems